Treatment with bosentan in a patient with thalassemia intermedia and pulmonary arterial hypertension

Blood

Volumn 120, Issue 7, 2012, Pages 1531-1532

  Anthi, Anastasia ^a   Tsangaris, Iraklis ^a   Hamodraka, Eftichia S ^a   Lekakis, John ^a   Armaganidis, Apostolos ^a   Orfanos, Stylianos E ^a  

^a UNIVERSITY OF ATHENS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN;

ADULT; ANTICOAGULANT THERAPY; BLOOD TRANSFUSION; CARDIOVASCULAR MAGNETIC RESONANCE; CASE REPORT; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE INCREASE; DYSPNEA; ERYTHROCYTE CONCENTRATE; FEMALE; FOLLOW UP; HEART CATHETERIZATION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IRON CHELATION; LETTER; LUNG ARTERY PRESSURE; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; PULMONARY HYPERTENSION; SPLENECTOMY; THALASSEMIA INTERMEDIA; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT OUTCOME; TREATMENT RESPONSE; TRICUSPID VALVE REGURGITATION;

EID: 84865191049     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-04-422568     Document Type: Letter

References (12)

1. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 2004;350(9): 886-895. (Pubitemid 38252536)
2. Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood. 2001;97(11):3411-3416.
3. Fonseca GH, Souza R, Salemi VM, Jardim CV, Gualandro SF. Pulmonary hypertension diagnosed by right heart catheterisation in sickle cell disease. Eur Respir J. 2012;39(1):112-118.
4. Taher AT, Musallam KM, Karimi M, et al. Overview on practices in thalassemia intermedia management aiming for lowering complication rates across a region of endemicity: the OPTIMAL CARE study. Blood. 2010;115(10):1886-1892.
5. Machado RF, Gladwin MT. Pulmonary hypertension in hemolytic disorders: pulmonary vascular disease: the global perspective. Chest. 2010;137(6 Suppl): S30-S38.
6. Simonneau G, Robbins IM, Beghetti M, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009;54(1 Suppl):S43-S54.
7. Minniti CP, Machado RF, Coles WA, Sachdev V, Gladwin MT, Kato GJ. Endothelin receptor antagonists for pulmonary hypertension in adult patients with sickle cell disease. Br J Haematol. 2009;147(5):737-43.
8. Barst RJ, Mubarak KK, Machado RF, et al. Exercise capacity and haemodynamics in patients with sickle cell disease with pulmonary hypertension treated with bosentan: results of the ASSET studies. Br J Haematol. 2010;149(3):426- 435.
9. Machado RF, Barst RJ, Yovetich NA, et al. Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood. 2011;118(4):855-864.
10. Derchi G, Forni GL, Formisano F, et al. Efficacy and safety of sildenafil in the treatment of severe pulmonary hypertension in patients with hemoglobinopathies. Haematologica. 2005;90(4):452-458. (Pubitemid 40592887)
11. Littera R, La Nasa G, Derchi G, Cappellini MD, Chang CY, Contu L. Long-term treatment with oral sildenafil in a thalassemic patient with pulmonary hypertension. Blood. 2002;100(4):1516-1517. (Pubitemid 34864323)
12. Anthi A, Machado RF, Jison ML, et al. Hemodynamic and functional assessment of patients with sickle cell disease and pulmonary hypertension. Am J Respir Crit Care Med. 2007;175(12):1272-1279. (Pubitemid 46905753)